We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

596 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 89 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 45

27% more call options, than puts

Call options by funds: $556M | Put options by funds: $439M

7% more funds holding

Funds holding: 559 → 596 (+37)

3% more capital inflows, than outflows

Capital inflows: $2.19B | Capital outflows: $2.13B

2% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 214

0.64% more ownership

Funds ownership: 95.31% → 95.95% (+0.64%)

0% more funds holding in top 10

Funds holding in top 10: 19 → 19 (0)

Holders
596
Holders Change
+37
Holders Change %
+6.62%
% of All Funds
14.81%
Holding in Top 10
19
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.47%
New
89
Increased
218
Reduced
214
Closed
45
Calls
$556​M
Puts
$439​M
Net Calls
+$117​M
Net Calls Change
-⁠$99​M

ALXN Hedge Fund Activity: Q3 2017 in Review

596 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.

Buyers outnumbered sellers: 89 funds opened new ALXN positions and 45 closed out — a net gain of 44 holders — while 218 added to existing stakes and 214 trimmed.

The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.

  • 596 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
  • Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
  • 89 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +44 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.

Based on aggregated 13F filings for Q3 2017.